Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation + Pembrolizumab or Avelumab in Metastatic Urothelial Carcinoma
NCT04701918Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2021
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, avelumab in urothelial carcinoma (UC), sponsored by Massachusetts General Hospital. Started Jun 2021; status: completed.
02
Drugs
pembrolizumabavelumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04701918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701918.